The Technical Analyst
Metacrine, Inc. [MTCR]
Exchange: NMS Sector: Healthcare Industry: Biotechnology
Metacrine, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.91% $0.470
Last updated: 16 May 2022 @ 10:50 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 19.82 mill |
| EPS: | -2.29 |
| P/E: | 0.000 |
| Earnings Date: | Aug 10, 2022 |
| SharesOutstanding: | 42.16 mill |
| Avg Daily Volume: | 1.703 mill |
| RATING 2022-05-13 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| True Range Average |
|---|
|
+/- $0.0540 ( +/- 11.94%) Range: 0.398 - 0.506 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-04-19 | Klassen Preston | Sell | 1 173 | Common Stock |
| 2022-04-19 | Klassen Preston | Sell | 43 575 | Common Stock |
| 2022-04-14 | Klassen Preston | Buy | 104 500 | Common Stock |
| 2022-02-27 | York Michael | Buy | 210 553 | Stock option (right to buy) |
| 2022-02-27 | York Michael | Buy | 210 553 | Stock option (right to buy) |
| INSIDER POWER |
|---|
| -5.86 |
| Last 100 transactions |
| Buy: 32 999 479 | Sell: 31 284 893 |
Forecast:
12:29 - $0.458
Live Trading Signals (every 1 min)
Forecast
1: 10:59 - $0.467
Forecast 2: 11:49 - $0.463
Forecast 3: 12:29 - $0.458
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.470 (3.91% ) |
| Volume | 0.136 mill |
| Avg. Vol. | 1.703 mill |
| % of Avg. Vol | 7.97 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MTCR
247 Signals | Accuracy: 8.10% | Accuracy Buy: 8.13% | Accuracy Sell: 8.06%
Avg return buy: -1.05 % | Avg return sell: 1.06 %
$1 invested is now $0.27 or -72.86% since 21-04-22
| Date | Signal | @ | Closed | % | May 16 - 10:41 | buy | $0.465 | N/A | Active |
|---|---|---|---|---|
| May 16 - 10:39 | sell | $0.455 | $0.465 @ May 16 - 10:40 | 2.18% |
| May 16 - 10:23 | buy | $0.459 | $0.455 @ May 16 - 10:38 | -0.85% |
| May 13 - 15:21 | sell | $0.452 | $0.459 @ May 16 - 10:22 | 1.50% |
| May 13 - 15:18 | buy | $0.457 | $0.452 @ May 13 - 15:20 | -0.94% |
| May 13 - 15:13 | sell | $0.452 | $0.457 @ May 13 - 15:16 | 1.04% |
| May 13 - 15:08 | buy | $0.457 | $0.452 @ May 13 - 15:12 | -1.05% |
| May 13 - 15:05 | sell | $0.452 | $0.459 @ May 13 - 15:06 | 1.48% |
| May 13 - 15:02 | buy | $0.456 | $0.452 @ May 13 - 15:04 | -0.75% |
| May 13 - 14:12 | sell | $0.451 | $0.459 @ May 13 - 15:01 | 1.82% |
MTCR
Latest Press Releases
2022-05-12 16:05:00 - Press Release
Metacrine Reports First-quarter 2022 Results
San diego, may 12, 2022 (globe newswire) -- metacrine, inc. (nasdaq:mtcr), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its first-quarter 2022 financial results and provided a business update.
2022-03-30 16:05:00 - Press Release
Metacrine Reports Fourth-quarter 2021 Results
San diego, march 30, 2022 (globe newswire) -- metacrine, inc. (nasdaq:mtcr), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its fourth-quarter 2021 financial results.
2022-02-11 08:05:00 - Press Release
Metacrine Updates Ibd Clinical Development Strategy And Implements Restructuring Plan
San diego, feb. 11, 2022 (globe newswire) -- metacrine, inc. (nasdaq:mtcr), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that it remains on track to begin a phase 2 clinical trial in ulcerative colitis. metacrine has received authorization from the u.s. food and drug administration (fda) to proceed with its phase 2 trial evaluating met642 in subjects with inflammatory bowel disease (ibd) and expects to begin the study in the first half of 2022.
2021-12-27 08:00:00 - Press Release
Metacrine Announces Resignation Of Chief Medical Officer
San diego, dec. 27, 2021 (globe newswire) -- metacrine, inc. (nasdaq:mtcr), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that hubert c. chen, m.d., chief medical officer, has resigned to pursue a new opportunity. dr. chen's resignation is effective december 31, 2021. preston klassen, m.d., mhs, chief executive officer, is expected to assume responsibility for metacrine's ongoing clinical trials and future clinical operations.
2021-11-11 08:00:00 - Press Release
Metacrine Reports Third-quarter 2021 Results
San diego, nov. 11, 2021 (globe newswire) -- metacrine, inc. (nasdaq:mtcr), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today reported its third-quarter 2021 financial results.
Latest News
2022-02-11 11:55:34 - Benzinga
Metacrine To Slash Its Workforce By 50%
Metacrine Inc (NASDAQ: MTCR) will ax half of its staff to conserve cash as it makes a last-stand drug development effort. Its shares are mired deep in penny stock territory after it floated its IPO in 2020 at $13/share.
2021-12-20 09:59:14 - Zacks Investment Research
Is the Options Market Predicting a Spike in Metacrine (MTCR) Stock?
Investors need to pay close attention to Metacrine (MTCR) stock based on the movements in the options market lately.
2021-12-15 15:52:22 - PennyStocks
3 Penny Stocks To Watch After Jerome Powell's Fed Announcement
3 penny stocks to watch after Fed Chair Powells press conference. The post 3 Penny Stocks To Watch After Jerome Powell's Fed Announcement appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-09-09 08:05:00 - GlobeNewsWire
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it has completed enrollment for its Phase 2a trial evaluating MET642, an optimized farnesoid X receptor (FXR) agonist, in patients with non-alcoholic steatohepatitis (NASH). The Company plans to report interim data from the first 60 patients early in the fourth quarter of 2021.
2021-09-08 08:05:00 - GlobeNewsWire
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m. ET. The event will showcase Metacrine's programs in non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD), as well as the introduction of a new discovery program.
2021-09-07 08:05:00 - GlobeNewsWire
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 a.m. ET on Monday, September 13, 2021.
2021-08-12 08:05:00 - GlobeNewsWire
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its second-quarter 2021 financial results.
2021-08-09 08:05:00 - GlobeNewsWire
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Canaccord Genuity Growth Conference at 12:30 p.m. ET on Thursday, August 12, 2021.
2021-07-06 08:05:00 - GlobeNewsWire
Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn's and Colitis Organisation (ECCO) 2021 Virtual Congress
SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present new preclinical data at the European Crohn's and Colitis Organisation (ECCO) 2021 Virtual Congress on July 9, 2021.
2021-06-17 08:05:00 - GlobeNewsWire
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present data at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2021, being held virtually from June 23-26, 2021. Data to be presented includes results from the Company's Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), as well as one oral presentation and one poster focused on preclinical studies examining FXR agonists in rare adult and pediatric cholestatic liver diseases.